Journey Medical (DERM) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
26 Jun, 2026Opening remarks and agenda
Meeting called to order by the CEO, with introductions of directors, legal counsel, COO, and independent auditors in attendance.
Agenda included accepting motions, collecting votes, and receiving a preliminary report from the Inspector of Elections.
Board and executive committee updates
Directors Lindsay A. Rosenwald, Claude Maraoui, Justin Smith, Miranda Toledano, Neil Herskowitz, and Michael Pearce were nominated for re-election to serve until the 2027 annual meeting.
Overview of voting outcomes
Quorum was confirmed with a majority of shares represented as of the record date.
All director nominees were elected and the appointment of KPMG as independent auditors for 2026 was ratified.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Journey Medical
- Q2 2026 revenue rose 23% to $18.5M, with Emrosi/EMROSI driving growth and net loss narrowing.DERM
Q2 2026 - Emrosi®'s clinical and commercial success positions it as the leading oral rosacea therapy.DERMInvestor presentation
- EMROSI drives rapid growth, with rising revenue, margins, and expanded market access.DERMA.G.P.'s Annual Virtual Healthcare Conference
- Q1 2026 revenue up 21% to $16M, net loss narrows, and EMROSI/Emrosi® expands market access.DERMQ1 2026
- Emrosi® drives revenue growth as the leading oral rosacea therapy, with expanding market access.DERMInvestor presentation
- Election of six directors and auditor ratification headline the 2026 annual meeting agenda.DERMProxy filing
- Virtual meeting to elect directors, ratify auditor, and review governance and compensation.DERMProxy filing
- Q2 revenue rose sequentially, profitability improved, and DFD-29 FDA review is pending.DERMQ2 2024
- Emrosi FDA approval and launch set the stage for transformational growth in 2025.DERMQ4 2024